CN109369433A - A kind of 5-ALA derivative, synthetic method and the application of F-18 label - Google Patents
A kind of 5-ALA derivative, synthetic method and the application of F-18 label Download PDFInfo
- Publication number
- CN109369433A CN109369433A CN201811264446.XA CN201811264446A CN109369433A CN 109369433 A CN109369433 A CN 109369433A CN 201811264446 A CN201811264446 A CN 201811264446A CN 109369433 A CN109369433 A CN 109369433A
- Authority
- CN
- China
- Prior art keywords
- ala
- added
- reaction
- label
- room temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
- A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
This application discloses 5-ALA derivative, synthetic method and the applications of a kind of F-18 label.It is long that the application implements the radioactive probe radioactive half-life provided, stability and fat-soluble is all substantially higher in 5-ALA.Compared with 5-ALA, the 5-ALA derivative of F-18 label can form higher concentration in pathological tissues, and concentration is lower in normal tissue, and toxicity is also smaller.And because its is fat-soluble more preferable, the ability for penetrating blood-brain barrier is stronger, can accurately be positioned to general tumour tissue, become broad spectrum type tumor developer.
Description
Technical field
This application involves organic compound synthesis technical field, in particular to a kind of 5-ALA of F-18 label
Derivative, synthetic method and application.
Background technique
Before 5-ALA (5-aminolevulinic acid, 5-ALA) is the endogenous of human body heme catabolism
Body substance is synthesized under the catalysis of 5-ALA synzyme in mitochondria by glycine and amber acyl coenzyme (Succinyl CoA).
Itself without light sensitivity, but it be metabolized in vivo after can generate the protoporphysin Ⅸ with near-infrared fluorescent and light sensitivity
(protoporphyrin Ⅸ, Pp Ⅸ).The forming process of protoporphysin Ⅸ is very slow in normal cell, and in ferrochelatase
(Ferrochelatase) under the action of and Fe2+Ion, which is formed, does not have photoactive ferroheme.But in malignant cell
The combined coefficient of protoporphysin Ⅸ is high and largely gathers, and issues near-infrared fluorescent (Near Infrared, NIR).Also, Pp Ⅸ
It is a kind of very effective photosensitizer, photochemical reaction occurs under the irradiation of certain wavelength light in it, generates creating singlet oxygen and oxygen
Compound, causes the damage of cell membrane, mitochondria and nucleic acid, to make cancer cell necrosis, apoptosis, plays the role for the treatment of [4].
Therefore 5-ALA is widely used in the diagnosis of various malignant tumours, treats the photodynamic therapy and light power diagnosis of tumour
In the tumor resection of guiding.
In view of advantage of the 5-ALA in terms of tumor imaging: 1) small molecule compound;2) before photosensitizer protoporphyrin Pp Ⅸ
Body;3) otherness of height is metabolized in tumour and normal tissue, if one can be constructed by radioisotope labeling
With very highly sensitive near-infrared fluorescent-radionuclide image double mode probe, the whole body of targeting is carried out to tumour
Imaging.
Many radionuclides have ideal physics, chemical property, but due to the molecule very little of 5-ALA, because
This can only be with will not be marked the positron radionuclide that its molecular structure affects greatly.Suzuki et al. first reported
It is carried out on 5 with the precursor that schiff bases activates11C methylation reaction, obtains11The radioactive probe of C flag11C-MALA.Then
Their preliminary assessments11C-MALA is absorbed in kinds of tumor cells and tumor model, and is drawn a conclusion,11The intake of C-MALA
It is highly relevant with the aggregation of Pp Ⅸ.Meanwhile from their data it can also be seen that, after injection in 1 minute to 60 minutes,11C-
The tumour of MALA intake is increasing always than the ratio of muscle, and probably there is no reach most within the time period for this numerical value
High point.But the nucleic for there was only 20 minutes for half-life period11For C, it has been the limit that 1 hour after injection, which is detected,.
Pippin etc. passes through use13N is marked, and the structure for not changing 5-ALA completely synthesizes13N-5-ALA, reaction speed is fast and imitates
Rate is high, and can observe the aggregation in tumour in Murine tumor model with PET.But it can be seen that from their data
In Glioma Model in situ, the intake of intake and normal cerebral tissue in tumour brain tissue only has in the when ratio of 10 minute-peaks
1.3 or so, this is very big the reason is that the half-life period because of 13N only has 9.96 minutes, and the biological half-life of 5-ALA in vivo is about
1 hour, therefore it is extremely difficult to ideal effect.For radioactive probe ideal for one, its radioactive half-life is answered
This is greater than the biological metabolism half-life period of the molecule in vivo, can just make have enough time to carry out body in the molecule of non-target organ in this way
Interior transport, metabolism and external discharge, obtain high target/background ratio.
Summary of the invention
It the 5-ALA derivative for being designed to provide a kind of F-18 label of the application, synthetic method and answers
With to solve the problems, such as radioactive probe half-life short in the prior art.
In a first aspect, according to an embodiment of the present application, a kind of 5-ALA derivative of F-18 label is provided,
Including 18F-ALA, chemical structure are as follows:
Wherein, n=1-6.
Second aspect provides a kind of 5-ALA derivative of F-18 label according to an embodiment of the present application,
Including 18F-O-ALA, chemical structure are as follows:
Wherein, n=2-4.
The third aspect provides a kind of 5-ALA derivative of F-18 label according to an embodiment of the present application
Synthetic method, comprising:
5-ALA is soluble in water, pH value is adjusted to 8.5, and the two dimethyl dicarbonate fourths for being dissolved in dioxane are added dropwise
Ester is stirred at room temperature 18h, extra di-tert-butyl dicarbonate is removed after reaction, aqueous solution is adjusted to acidity, is extracted with ethyl acetate
Obtain 5-N- t-butoxycarbonyl amino levulic acid;
By the 5-N- t-butoxycarbonyl amino levulic acid, dimethylamino naphthyridine and glycol stir under ice bath, are added
Carbodiimide, ice bath stirring 2h, room temperature continue to stir 48h, and solvent is spin-dried for after reaction, water is added, is extracted with ethyl acetate,
Organic phase is cleaned with 10% NaHCO3 solution after collected organic layer, finally carries out post separation, obtains pale yellow powder shape
HBA, the glycol include diethanol, two butanol or two hexanols;
The HBA is added in dry pyridine, paratoluensulfonyl chloride is added portionwise under ice bath, is then gradually restored to room
Temperature is stirred overnight, and post separation after solution concentration, obtains precursor THBA after reaction;
Accelerator outflow comes18F-Ion is captured by QMA column, is then eluted to reaction tube with amino-polyether/potassium carbonate, is added
Acetonitrile removes dry solvent repeatedly, is added in reaction tube the precursor THBA and is dissolved in dry acetonitrile, is heated at reflux and is reacted, instead
Should after be added HCl solution heating deprotection group, after being diluted with water use solid-phase extraction column preliminary purification, finally use efficient liquid phase
Chromatography carries out post separation, obtains18F-ALA。
Fourth aspect provides a kind of 5-ALA derivative of F-18 label according to an embodiment of the present application
Synthetic method, including;
5-ALA is soluble in water, pH value is adjusted to 8.5, and the two dimethyl dicarbonate fourths for being dissolved in dioxane are added dropwise
Ester is stirred at room temperature 18h, extra di-tert-butyl dicarbonate is removed after reaction, aqueous solution is adjusted to acidity, is extracted with ethyl acetate
Obtain 5-N- t-butoxycarbonyl amino levulic acid;
By the 5-N- t-butoxycarbonyl amino levulic acid, dimethylamino naphthyridine, and, diethylene glycol, triethylene glycol
It is stirred under ice bath with one of tetraethylene glycol, carbodiimide, ice bath stirring 2h is added, room temperature continues to stir 48h, after reaction
Be spin-dried for solvent, water be added, is extracted with ethyl acetate, after collected organic layer with 10% NaHCO3Solution cleans organic phase,
Post separation is finally carried out, the HEBA of pale yellow powder shape is obtained;
The HEBA is added in dry pyridine, paratoluensulfonyl chloride is added portionwise under ice bath, is then gradually restored to
Room temperature is stirred overnight, and post separation after solution concentration, obtains precursor TEBA after reaction;
Accelerator outflow comes18F-Ion is captured by QMA column, is then eluted to reaction tube with amino-polyether/potassium carbonate, is added
Acetonitrile removes dry solvent repeatedly, is added in reaction tube the precursor TEBA and is dissolved in dry acetonitrile, is heated at reflux and is reacted, instead
Should after be added HCl solution heating deprotection group, after being diluted with water use solid-phase extraction column preliminary purification, finally use efficient liquid phase
Chromatography carries out post separation, obtains18F-O-ALA。
5th aspect provides the 5-ALA derivative application of F-18 label according to an embodiment of the present application,
For detecting tumour.
6th aspect provides the 5-ALA derivative application of F-18 label according to an embodiment of the present application,
For detecting tumour.
From the above technical scheme, the 5-ALA that the embodiment of the present application provides a kind of F-18 label derives
Object, synthetic method and application.It is long that the application implements the radioactive probe radioactive half-life provided, stability and fat-soluble all bright
It is powerful and influential to be higher than 5-ALA.Compared with ALA, the 5-ALA derivative of F-18 label can be formed more in pathological tissues
High concentration, and concentration is lower in normal tissue, toxicity is also smaller.And because of the fat-soluble more preferable of its, penetration rate of blood brain screen
The ability of barrier is stronger, can accurately be positioned to general tumour tissue, become broad spectrum type tumor developer.
Specific embodiment
According to an embodiment of the present application, a kind of 5-ALA derivative of F-18 label is provided, including18F-
ALA, chemical structure are as follows:
Wherein, n=1-6.
As n=1,18The chemical structure of F-ALA-1 are as follows:
18The compound identification data of F-ALA-1:
Mass spectrum (ES+) m/z:177.08
Hydrogen spectrum1H NMR(CDCl3):δ1.52(t,2H),δ2.74(t,2H),δ2.84(t,2H),δ3.81(t,2H),δ
4.28(t,2H),δ4.37(t,2H)。
As n=2,18The chemical structure of F-ALA-2 are as follows:
18The compound identification data of F-ALA-2:
Mass spectrum (ES+) m/z:205.11
Hydrogen spectrum1H NMR(CDCl3):δ1.49(m,2H),δ1.53(t,2H),δ1.62(m,2H),δ2.74(t,2H),δ
2.84(t,2H),δ3.81(t,2H),δ4.09(t,2H),δ4.13(t,2H)。
As n=3,18The chemical structure of F-ALA-3 are as follows:
18The compound identification data of F-ALA-3:
Mass spectrum (ES+) m/z:233.14
Hydrogen spectrum1H NMR(CDCl3): δ 1.43 (m, 2H), δ 1.49 (m, 2H), δ 1.53 (t, 2H), δ 1.62 (m, 2H), δ
2.74 (t, 2H), δ 2.84 (t, 2H), δ 3.84 (t, 2H), δ 4.13 (t, 2H).
As n=4,18The chemical structure of F-ALA-4 are as follows:
18The compound identification data of F-ALA-4:
Mass spectrum (ES+) m/z:261.17
Hydrogen spectrum1H NMR(CDCl3):δ1.29(m,6H),δ1.43(m,2H),δ1.49(m,2H),δ1.53(t,2H),δ
1.62(m,2H),δ2.74(t,2H),δ2.84(t,2H),δ3.81(t,2H),δ4.09(t,2H),δ4.13(t,2H)。
As n=5,18The chemical structure of F-ALA-5 are as follows:
18The compound identification data of F-ALA-5:
Mass spectrum (ES+) m/z:289.21
Hydrogen spectrum1H NMR(CDCl3):δ1.29(m,10H),δ1.43(m,2H),δ1.49(m,2H),δ1.53(t,2H),δ
1.62(m,2H),δ2.74(t,2H),δ2.84(t,2H),δ3.81(t,2H),δ4.09(t,2H),δ4.13(t,2H)。
As n=6,18The chemical structure of F-ALA-6 are as follows:
18The compound identification data of F-ALA-6:
Mass spectrum (ES+) m/z:317.24
Hydrogen spectrum1H NMR(CDCl3):δ1.26(m,4H),δ1.29(m,10H),δ1.43(m,2H),δ1.49(m,2H),δ
1.53(t,2H),δ1.62(m,2H),δ2.74(t,2H),δ2.84(t,2H),δ3.81(t,2H),δ4.09(t,2H),δ4.13
(t,2H)。
According to an embodiment of the present application, a kind of 5-ALA derivative of F-18 label is provided, including18F-O-
ALA, chemical structure are as follows:
Wherein, n=2-4.
As n=2,18The chemical structure of F-O-ALA-2 are as follows:
18The compound identification data of F-O-ALA-2:
Mass spectrum (ES+) m/z:220.11
Hydrogen spectrum1H NMR(CDCl3):δ1.53(t,2H),δ2.74(t,2H),δ2.84(t,2H),δ3.57(t,2H),δ
3.65(t,2H),δ3.81(t,2H),δ4.20(t,2H),δ4.26(t,2H)。
As n=3,18The chemical structure of F-O-ALA-3 are as follows:
18The compound identification data of F-O-ALA-3:
Mass spectrum (ES+) m/z:264.14
Hydrogen spectrum1H NMR(CDCl3):δ1.53(t,2H),δ2.74(t,2H),δ2.84(t,2H),δ3.54(m,4H),δ
3.57(t,2H),δ3.65(t,2H),δ3.81(t,2H),δ4.20(t,2H),δ4.26(t,2H)。
As n=4,18The chemical structure of F-O-ALA-4 are as follows:
18The compound identification data of F-O-ALA-4:
Mass spectrum (ES+) m/z:308.16
Hydrogen spectrum1H NMR(CDCl3):δ1.53(t,2H),δ2.74(t,2H),δ2.84(t,2H),δ3.54(m,8H),δ
3.57(t,2H),δ3.65(t,2H),δ3.81(t,2H),δ4.20(t,2H),δ4.26(t,2H)。
According to an embodiment of the present application, a kind of 5-ALA derivative synthesizing process of F-18 label is provided,
Include:
5-ALA is soluble in water, pH value is adjusted to 8.5, and the two dimethyl dicarbonate fourths for being dissolved in dioxane are added dropwise
Ester is stirred at room temperature 18h, extra di-tert-butyl dicarbonate is removed after reaction, aqueous solution is adjusted to acidity, is extracted with ethyl acetate
Obtain 5-N- t-butoxycarbonyl amino levulic acid;
By the 5-N- t-butoxycarbonyl amino levulic acid, dimethylamino naphthyridine and glycol stir under ice bath, are added
Carbodiimide, ice bath stirring 2h, room temperature continue to stir 48h, and solvent is spin-dried for after reaction, water is added, is extracted with ethyl acetate,
After collected organic layer with 10% NaHCO3Solution cleans organic phase, finally carries out post separation, obtains the HBA of pale yellow powder shape
(6-hydroxyhexyl 5- ((tert-butoxycarbonyl) amino) -4-oxopentanoate), the glycol includes
Diethanol, two butanol or two hexanols;
The HBA is added in dry pyridine, paratoluensulfonyl chloride is added portionwise under ice bath, is then gradually restored to room
Temperature is stirred overnight, and post separation after solution concentration, obtains precursor THBA (6- (tosyloxy) hexyl5- ((tert- after reaction
butoxycarbonyl)amino)-4-oxopentanoate);
Accelerator outflow comes18F-Ion is captured by QMA column, is then eluted to reaction tube with amino-polyether/potassium carbonate, is added
Acetonitrile removes dry solvent repeatedly, is added in reaction tube the precursor THBA and is dissolved in dry acetonitrile, is heated at reflux and is reacted, instead
Should after be added HCl solution heating deprotection group, after being diluted with water use solid-phase extraction column preliminary purification, finally use efficient liquid phase
Chromatography carries out post separation, obtains18F-ALA。
18F-ALA synthetic route is as follows.
With18For F-ALA-3, synthetic method is as follows:
1. the synthesis of precursor compound THBA.
The conjunction of A.Boc-5-ALA (5- ((tert-butoxycarbonyl) amino) -4-oxopentanoic acid)
At.
5-ALA is dissolved in 5mL water, and adjusts pH value to 8.5 with the NaOH of 1N, is then added dropwise and is dissolved in 5mL dioxy six
The di-tert-butyl dicarbonate ((Boc) of ring2O) (the 1-2 times of mole relative to 5-ALA), stirs 18h at room temperature.It is more after reaction
Remaining (Boc)2O is extracted with ether and is removed, and aqueous solution is adjusted to acidity with the HCl solution of 1N, is then extracted with ethyl acetate to obtain
Boc-5-ALA, vacuum distillation obtain colorless oil after being spin-dried for.
The synthesis of B.HBA.
Boc-5-ALA, dimethylamino naphthyridine (DMAP) and 1, bis- hexanol of 6- is according to the molar ratio of 1:1:1 under ice bath
Stirring is added and Boc-5-ALA is with the carbodiimide of mole, and 2h is then stirred under ice bath, continues to stir later at room temperature
48h.Be spin-dried for solvent after reaction, water be added, is then extracted with ethyl acetate, after collected organic layer with 10% NaHCO3It is molten
Liquid cleans organic phase.Finally carry out post separation (MeOH:CH2Cl2=40:1) obtain pale yellow powder shape HBA.
C. the synthesis of precursor THBA.
HBA is added in dry 5mL pyridine, the paratoluensulfonyl chloride of 2-3 times of mole is added portionwise under ice bath
(TsCl), it is then gradually restored to room temperature, is stirred overnight.Post separation after solution concentration after reaction.
2. radioactive probe18The labelled synthesis of F-ALA-3.
Accelerator outflow comes18F-Ion is captured by QMA column, then uses K222/K2CO3It is eluted to reaction tube, adds acetonitrile anti-
Dry solvent is removed again.Then the HBA for being added in reaction tube 5-20mg is dissolved in the dry acetonitrile of 1mL, is heated at reflux and is reacted.Instead
Should after be added 2M HCl solution heating deprotection group, after being then diluted with water use solid-phase extraction column preliminary purification, finally use
HPLC carries out post separation, finally obtains18Radiochemical purity > 95% of F-ALA-3.
18F-ALA-3 synthetic route is as follows:
According to an embodiment of the present application, a kind of 5-ALA derivative synthesizing process of F-18 label is provided,
Including;
5-ALA is soluble in water, pH value is adjusted to 8.5, and the two dimethyl dicarbonate fourths for being dissolved in dioxane are added dropwise
Ester is stirred at room temperature 18h, extra di-tert-butyl dicarbonate is removed after reaction, aqueous solution is adjusted to acidity, is extracted with ethyl acetate
Obtain 5-N- t-butoxycarbonyl amino levulic acid;
By the 5-N- t-butoxycarbonyl amino levulic acid, dimethylamino naphthyridine, and, diethylene glycol, triethylene glycol
It is stirred under ice bath with one of tetraethylene glycol, carbodiimide, ice bath stirring 2h is added, room temperature continues to stir 48h, after reaction
Be spin-dried for solvent, water be added, is extracted with ethyl acetate, after collected organic layer with 10% NaHCO3Solution cleans organic phase,
Post separation is finally carried out, HEBA (2- (2-hydroxyethoxy) the ethyl5- ((tert- of pale yellow powder shape is obtained
butoxycarbonyl)amino)-4-oxopentanoate);
The HEBA is added in dry pyridine, paratoluensulfonyl chloride is added portionwise under ice bath, is then gradually restored to
Room temperature is stirred overnight, and post separation after solution concentration, obtains precursor TEBA (2- (2- (tosyloxy) ethoxy) after reaction
ethyl5-((tert-butoxycarbonyl)amino)-4-oxopentanoate);
Accelerator outflow comes18F-Ion is captured by QMA column, is then eluted to reaction tube with amino-polyether/potassium carbonate, is added
Acetonitrile removes dry solvent repeatedly, is added in reaction tube the precursor TEBA and is dissolved in dry acetonitrile, is heated at reflux and is reacted, instead
Should after be added HCl solution heating deprotection group, after being diluted with water use solid-phase extraction column preliminary purification, finally use efficient liquid phase
Chromatography carries out post separation, obtains18F-O-ALA。
18F-O-ALA synthetic route is as follows.
With18For F-O-ALA-2, synthetic method is as follows:
1. the synthesis of precursor compound TEBA.
The synthesis of A.Boc-5-ALA.
5-ALA is dissolved in 5mL water, and adjusts pH value to 8.5 with the NaOH of 1N, is then added dropwise and is dissolved in 5mL dioxy six
The di-tert-butyl dicarbonate ((Boc) of ring2O) (the 1-2 times of mole relative to 5-ALA), stirs 18h at room temperature.It is more after reaction
Remaining (Boc)2O is extracted with ether and is removed, and aqueous solution is adjusted to acidity with the HCl solution of 1N, is then extracted with ethyl acetate to obtain
Boc-5-ALA, vacuum distillation obtain colorless oil after being spin-dried for.
The synthesis of B.HEBA.
Boc-5-ALA, dimethylamino naphthyridine (DMAP) and diethylene glycol stir under ice bath according to the molar ratio of 1:1:1
The carbodiimide being added with mole is mixed, 2h is then stirred under ice bath, continues to stir 48h later at room temperature.React back spin
Dry solvent, be added water, then extracted with ethyl acetate, after collected organic layer with 10% NaHCO3Solution cleaning is organic
Phase.Finally carry out post separation (MeOH:CH2Cl2=40:1) obtain pale yellow powder shape HEBA.
C. the synthesis of precursor TEBA.
HEBA is added in dry 5mL pyridine, the paratoluensulfonyl chloride of 2-3 times of mole is added portionwise under ice bath
(TsCl), it is then gradually restored to room temperature, is stirred overnight.Post separation after solution concentration after reaction.
2. radioactive probe18The labelled synthesis of F-O-ALA-2.
Accelerator outflow comes18F-Ion is captured by QMA column, then uses K222/K2CO3It is eluted to reaction tube, adds acetonitrile anti-
Dry solvent is removed again.Then the TEBA for being added in reaction tube 5-20mg is dissolved in the dry acetonitrile of 1mL, is heated at reflux and is reacted.
2M HCl solution is added after reaction and heats deprotection group, solid-phase extraction column preliminary purification is used after being then diluted with water, finally
Post separation is carried out with HPLC, is finally obtained18Radiochemical purity > 95% of F-O-ALA-2.
18F-O-ALA-2 synthetic route is as follows
According to an embodiment of the present application, the 5-ALA derivative application of F-18 label, the 5- ammonia are provided
Base levulic acid derivative includes18F-ALA, for detecting tumour.
Tumor model is made using nude mice, mice with tumor anesthesia is placed on animal PET/CT, then from tail vein injection
0.1-0.5mCi's18F-ALA solution carries out PET/CT imaging after being metabolized 0.5-2 hours in vivo.
With AsPC-1 cell construction tumor model, from tail vein injection 0.1-0.5mCi's18F-ALA-3 probe, exists respectively
The value that the γ of each organ in tumor mouse is counted, i.e. radiopharmaceutical 18F- are detected after injection after 10 minutes, 1 hour and 2 hours
The amount and tumour of ALA-3 and the ratio of muscle, experimental result are as shown in table 1.
Table 1
10 minutes | 60 minutes | 120 minutes | |
Blood | 4.56±1.34 | 1.14±0.47 | 0.96±0.11 |
Brain | 0.62±0.21 | 1.02±0.33 | 1.24±0.18 |
Heart | 2.78±0.41 | 1.48±0.09 | 0.96±0.09 |
Lung | 4.21±0.62 | 2.64±0.29 | 1.26±0.20 |
Liver | 9.67±0.63 | 3.32±0.52 | 2.37±0.31 |
Spleen | 13.92±0.58 | 4.30±0.12 | 3.20±0.29 |
Pancreas | 2.24±0.15 | 1.64±0.30 | 1.08±0.09 |
Stomach | 2.99±0.47 | 1.24±0.31 | 1.02±0.08 |
Intestines | 7.17±0.59 | 3.98±0.53 | 2.15±0.76 |
Kidney | 74.30±7.97 | 38.64±5.20 | 18.48±3.24 |
Muscle | 1.02±0.08 | 0.61±0.09 | 0.59±0.08 |
Bone | 3.02±0.26 | 1.10±0.47 | 1.02±0.23 |
Tumour | 3.98±0.74 | 5.89±0.65 | 5.94±0.38 |
Tumour/muscle | 3.90±0.71 | 9.66±0.93 | 10.07±0.98 |
Seen from table 1,18F-ALA-3 shows in the internal distributed data of tumor mouse18F-ALA-3 has higher in tumour
Intake, and the ratio of tumour and muscle is higher, can be used as the imaging agent of target tumor.
According to an embodiment of the present application, the 5-ALA derivative application of F-18 label, the 5- ammonia are provided
Base levulic acid derivative includes18F-O-ALA, for detecting tumour.
With AsPC-1 cell construction tumor model, from tail vein injection 0.1-0.5mCi's18F-O-ALA-2 probe, respectively
The value that the γ of each organ in tumor mouse is counted, i.e. radiopharmaceutical are detected behind 10 minutes after injection, 1 hour and 2 hours18F-O-
The amount and tumour of ALA-2 and the ratio of muscle, experimental result are as shown in table 2.
Table 2
10 minutes | 60 minutes | 120 minutes | |
Blood | 4.02±1.55 | 1.02±0.35 | 0.87±0.23 |
Brain | 0.53±0.16 | 0.87±0.26 | 1.02±0.24 |
Heart | 3.64±0.87 | 1.76±0.22 | 0.95±0.07 |
Lung | 4.89±1.02 | 3.42±0.43 | 1.33±0.27 |
Liver | 7.69±1.27 | 3.04±0.67 | 1.99±0.43 |
Spleen | 11.34±2.04 | 3.89±0.46 | 2.87±0.22 |
Pancreas | 2.36±0.75 | 1.56±0.45 | 1.01±0.06 |
Stomach | 3.45±0.96 | 1.99±0.57 | 1.43±0.07 |
Intestines | 8.78±1.69 | 4.84±1.24 | 2.96±0.24 |
Kidney | 79.9±6.86 | 49.96±6.32 | 20.32±2.68 |
Muscle | 1.32±0.07 | 0.66±0.08 | 0.52±0.06 |
Bone | 3.45±0.31 | 1.14±0.55 | 0.99±0.35 |
Tumour | 4.01±0.53 | 5.97±1.02 | 6.26±0.47 |
Tumour/muscle | 3.04±0.35 | 9.05±1.24 | 12.04±0.66 |
As can be seen from Table 2,18F-O-ALA-2 probe shows respectively in vivo tumor mouse18F-O-ALA-2 has in tumour
The ratio of higher intake, tumour and muscle is higher, can be used as the imaging agent of target tumor.
From the above technical scheme, the 5-ALA that the embodiment of the present application provides a kind of F-18 label derives
Object, synthetic method and application.It is long that the application implements the radioactive probe radioactive half-life provided, stability and fat-soluble all bright
It is powerful and influential to be higher than 5-ALA.Compared with ALA, the 5-ALA derivative of F-18 label can be formed more in pathological tissues
High concentration, and concentration is lower in normal tissue, toxicity is also smaller.And because of the fat-soluble more preferable of its, penetration rate of blood brain screen
The ability of barrier is stronger, can accurately be positioned to general tumour tissue, become broad spectrum type tumor developer.
Those skilled in the art will readily occur to its of the application after considering specification and practicing application disclosed herein
Its embodiment.This application is intended to cover any variations, uses, or adaptations of the application, these modifications, purposes or
Person's adaptive change follows the general principle of the application and including the undocumented common knowledge in the art of the application
Or conventional techniques.The description and examples are only to be considered as illustrative, and the true scope and spirit of the application are by following
Claim is pointed out.
It should be understood that the application is not limited to the precise structure that has been described above and shown in the drawings, and
And various modifications and changes may be made without departing from the scope thereof.Scope of the present application is only limited by the accompanying claims.
Claims (6)
1. a kind of 5-ALA derivative of F-18 label, which is characterized in that including18F-ALA, chemical structure are as follows:
Wherein, n=1-6.
2. a kind of 5-ALA derivative of F-18 label, which is characterized in that including18F-O-ALA, chemical structure
Are as follows:
Wherein, n=2-4.
3. a kind of 5-ALA derivative synthesizing process of F-18 label as described in claim 1, which is characterized in that
Include:
5-ALA is soluble in water, pH value is adjusted to 8.5, and the di-tert-butyl dicarbonate for being dissolved in dioxane is added dropwise,
18h is stirred at room temperature, extra di-tert-butyl dicarbonate is removed after reaction, aqueous solution is adjusted to acidity, is extracted with ethyl acetate
To 5-N- t-butoxycarbonyl amino levulic acid;
By the 5-N- t-butoxycarbonyl amino levulic acid, dimethylamino naphthyridine and glycol stir under ice bath, and carbon two is added
Imines, ice bath stirring 2h, room temperature continue to stir 48h, and solvent is spin-dried for after reaction, water is added, is extracted with ethyl acetate, is collected
After organic layer with 10% NaHCO3Solution cleans organic phase, finally carries out post separation, obtains the HBA of pale yellow powder shape, institute
Stating glycol includes diethanol, two butanol or two hexanols;
The HBA is added in dry pyridine, paratoluensulfonyl chloride is added portionwise under ice bath, is then gradually restored to room temperature,
It is stirred overnight, post separation after solution concentration, obtains precursor THBA after reaction;
Accelerator outflow comes18F-Ion is captured by QMA column, is then eluted to reaction tube with amino-polyether/potassium carbonate, is added acetonitrile
Dry solvent is removed repeatedly, is added in reaction tube the precursor THBA and is dissolved in dry acetonitrile, is heated at reflux and is reacted, after reaction
HCl solution is added and heats deprotection group, solid-phase extraction column preliminary purification is used after being diluted with water, finally uses high performance liquid chromatography
Method carries out post separation, obtains18F-ALA。
4. a kind of 5-ALA derivative synthesizing process of F-18 label as claimed in claim 2, which is characterized in that
Including;
5-ALA is soluble in water, pH value is adjusted to 8.5, and the di-tert-butyl dicarbonate for being dissolved in dioxane is added dropwise,
18h is stirred at room temperature, extra di-tert-butyl dicarbonate is removed after reaction, aqueous solution is adjusted to acidity, is extracted with ethyl acetate
To 5-N- t-butoxycarbonyl amino levulic acid;
By the 5-N- t-butoxycarbonyl amino levulic acid, dimethylamino naphthyridine, and, diethylene glycol, triethylene glycol and four
One of ethylene glycol stirs under ice bath, and carbodiimide, ice bath stirring 2h is added, and room temperature continues to stir 48h, be spin-dried for after reaction
Solvent, be added water, extracted with ethyl acetate, after collected organic layer with 10% NaHCO3Solution cleans organic phase, finally
Post separation is carried out, the HEBA of pale yellow powder shape is obtained;
The HEBA is added in dry pyridine, paratoluensulfonyl chloride is added portionwise under ice bath, is then gradually restored to room temperature,
It is stirred overnight, post separation after solution concentration, obtains precursor TEBA after reaction;
Accelerator outflow comes18F-Ion is captured by QMA column, is then eluted to reaction tube with amino-polyether/potassium carbonate, is added acetonitrile
Dry solvent is removed repeatedly, is added in reaction tube the precursor TEBA and is dissolved in dry acetonitrile, is heated at reflux and is reacted, after reaction
HCl solution is added and heats deprotection group, solid-phase extraction column preliminary purification is used after being diluted with water, finally uses high performance liquid chromatography
Method carries out post separation, obtains18F-O-ALA。
5. a kind of 5-ALA derivative application of F-18 label as described in claim 1, which is characterized in that be used for
Detect tumour.
6. a kind of 5-ALA derivative application of F-18 label as claimed in claim 2, which is characterized in that be used for
Detect tumour.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811264446.XA CN109369433B (en) | 2018-10-29 | 2018-10-29 | F-18 labeled 5-aminolevulinic acid derivative, and synthesis method and application thereof |
PCT/CN2019/073553 WO2020087794A1 (en) | 2018-10-29 | 2019-01-29 | F-18 labeled 5-aminolevulinic acid derivative, synthesis method therefor, and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811264446.XA CN109369433B (en) | 2018-10-29 | 2018-10-29 | F-18 labeled 5-aminolevulinic acid derivative, and synthesis method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109369433A true CN109369433A (en) | 2019-02-22 |
CN109369433B CN109369433B (en) | 2020-01-17 |
Family
ID=65390196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811264446.XA Active CN109369433B (en) | 2018-10-29 | 2018-10-29 | F-18 labeled 5-aminolevulinic acid derivative, and synthesis method and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN109369433B (en) |
WO (1) | WO2020087794A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020087794A1 (en) * | 2018-10-29 | 2020-05-07 | 庄晓青 | F-18 labeled 5-aminolevulinic acid derivative, synthesis method therefor, and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101723850A (en) * | 2008-10-10 | 2010-06-09 | 北京师范大学 | Novel 18F labeled aromatic amino acids, preparation method and application thereof in tumor imaging |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856566A (en) * | 1997-09-02 | 1999-01-05 | Dusa Pharmaceuticals, Inc. | Sterilized 5-aminolevulinic acid |
CN109369433B (en) * | 2018-10-29 | 2020-01-17 | 庄晓青 | F-18 labeled 5-aminolevulinic acid derivative, and synthesis method and application thereof |
-
2018
- 2018-10-29 CN CN201811264446.XA patent/CN109369433B/en active Active
-
2019
- 2019-01-29 WO PCT/CN2019/073553 patent/WO2020087794A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101723850A (en) * | 2008-10-10 | 2010-06-09 | 北京师范大学 | Novel 18F labeled aromatic amino acids, preparation method and application thereof in tumor imaging |
Non-Patent Citations (1)
Title |
---|
ADAM B.PIPPIN: "Radiochemical synthesis and evaluation of 13N-labeled 5-aminolevulinic acid for PET imaging of gliomas", 《ACS MEDICINAL CHEMISTRY LETTES》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020087794A1 (en) * | 2018-10-29 | 2020-05-07 | 庄晓青 | F-18 labeled 5-aminolevulinic acid derivative, synthesis method therefor, and application thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2020087794A1 (en) | 2020-05-07 |
CN109369433B (en) | 2020-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220088229A1 (en) | Psma-binding agents and uses thereof | |
US10882871B2 (en) | 18/19F-labelled compounds which target the prostate specific membrane antigen | |
ES2663496T3 (en) | Precursor compound of radioactive halogen-labeled organic compound | |
EP2864329B1 (en) | 18f-labelled folate/antifolate analogues | |
JP6661010B2 (en) | Peptide thiourea derivative, radioisotope-labeled compound containing the same, and pharmaceutical composition containing the same as active ingredient for treating or diagnosing prostate cancer | |
CN107353323B (en) | Al18F-labeled PSMA (PSMA) targeted inhibitor and preparation method and application thereof | |
JP2009149678A (en) | Tumor imaging compound | |
CN113372285B (en) | Prostate specific membrane antigen inhibitor, radionuclide marker, preparation method and application thereof | |
JPWO2009078396A1 (en) | Method for producing radioactive fluorine-labeled organic compound | |
EP2150514B1 (en) | 18f-labelled folates | |
CN109369433A (en) | A kind of 5-ALA derivative, synthetic method and the application of F-18 label | |
Heinrich et al. | Synthesis of fluorine-18 labeled rhodamine B: A potential PET myocardial perfusion imaging agent | |
JP2021511329A (en) | Positron emission tomography of transport protein overexpression-related diseases Radiotracer, transport protein target ligand for fluorescence imaging and photodynamic therapy and its production method | |
US20200188540A1 (en) | Conformationally strained trans-cycloalkenes for radiolabeling | |
Bhadwal et al. | Synthesis and biological evaluation of 177Lu-DOTA-porphyrin conjugate: a potential agent for targeted tumor radiotherapy | |
EP3216796B1 (en) | Phosphonium compound and production method therefor | |
CN111362828A (en) | A kind of18F-labeled fluoropropionylated ornithine as well as preparation method and application thereof | |
US9382202B2 (en) | Precursor for labeling therapeutic agent for liver cancer and method for manufacturing the same | |
US20220072165A1 (en) | Radiodrug for diagnostic/therapeutic use in nuclear medicine and radio-guided medicine | |
ES2693126T3 (en) | PET / SPECT agents for applications in biomedical imaging | |
US20230263915A1 (en) | Radiolabeled compounds | |
CN102336908B (en) | <99m>Tc complex, and preparation method, intermediate and application thereof | |
US20200376147A1 (en) | Sodium saccharin having conjugated ligand, derivatives thereof and process for the preparation thereof | |
Boss | Synthesis and Evaluation of Novel Folate Tracers for Tumor Imaging Using PET | |
비나이 | Studies of Lipophilic Complexes of Mangan Family (VIIB) Radionuclides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |